Pentoxifylline in the Treatment of Cutaneous Leishmaniasis: A Randomized Clinical Trial in Colombia
Authors:
- Maria del Mar CastroMCMaria del Mar Castro
- Alexandra CossioACAlexandra Cossio
- Adriana NavasANAdriana Navas
- Olga FernandezOFOlga Fernandez
- Liliana ValderramaLVLiliana Valderrama
- Lyda Cuervo-PardoLCLyda Cuervo-Pardo
- Ricardo Marquez-OñateRMRicardo Marquez-Oñate
- María Adelaida GómezMGMaría Adelaida Gómez
- Nancy Gore SaraviaNSNancy Gore Saravia
Open Access
Abstract
Addition of the immunomodulator pentoxifylline (PTX) to antimonial treatment of mucosal leishmaniasis has shown increased efficacy. This randomized, double-blind, placebo-controlled trial evaluated whether addition of pentoxifylline to meglumine antimoniate (MA) treatment improves therapeutic response in cutaneous leishmaniasis (CL) patients. Seventy-three patients aged 18–65 years, having multiple lesions or a single lesion ≥ 3 cm were randomized to receive: intramuscular MA (20 mg/kg/day × 20 days) plus oral PTX 400 mg thrice daily (intervention arm, n = 36) or MA plus placebo (control arm, n = 37), between 2012 and 2015. Inflammatory gene expression was evaluated by RT-qPCR in peripheral blood mononuclear cells from trial patients, before and after treatment. Intention-to-treat failure rate was 35% for intervention vs. 25% for control (OR: 0.61, 95% CI: 0.21–1.71). Per-protocol failure rate was 32% for PTX, and 24% for placebo (OR: 0.50, 95% CI: 0.13–1.97). No differences in frequency or severity of adverse events were found (PTX = 142 vs. placebo = 140). Expression of inflammatory mediators was unaltered by addition of PTX to MA. However, therapeutic failure was associated with significant overexpression of il1β and ptgs2 (p < 0.05), irrespective of study group. No clinical benefit of addition of PTX to standard treatment was detected in early mild to moderate CL caused by Leishmania (V.) panamensis.Keywords
Funding Information
- Departamento Administrativo de Ciencia, Tecnología e Innovación (COLCIENCIAS) (222951928964)
- National Institute of Allergy and Infectious Diseases (AI093775-01, 1U19AI129910-01)
This publication has 38 references indexed in Scilit:
- Mucosal Leishmaniasis: An Underestimated Presentation of a Neglected DiseaseBioMed Research International, 2013
- Interventions for American Cutaneous and Mucocutaneous Leishmaniasis: A Systematic Review UpdatePLOS ONE, 2013
- Noninferiority of Miltefosine Versus Meglumine Antimoniate for Cutaneous Leishmaniasis in ChildrenThe Journal of Infectious Diseases, 2012
- Systematic review of the adverse effects of cutaneous leishmaniasis treatment in the New WorldActa Tropica, 2011
- Oral Pentoxifylline Combined with Pentavalent Antimony: A Randomized Trial for Mucosal LeishmaniasisClinical Infectious Diseases, 2007
- Pharmacokinetics of Antimony in Children Treated for Leishmaniasis with Meglumine AntimoniateThe Journal of Infectious Diseases, 2007
- Effect of combination therapy with systemic glucantime and pentoxifylline in the treatment of cutaneous leishmaniasisInternational Journal of Dermatology, 2006
- Effect of Pentoxifylline on Levels of Pro‐inflammatory Cytokines During Chronic Hepatitis CScandinavian Journal of Immunology, 2006
- Effects of Phosphodiesterase Inhibition on the Inflammatory Response after Shock: Role of Pentoxifylline2004
- Circadian Variations in the Pharmacokinetics of Pentoxifylline in ManJournal of Pharmacy and Pharmacology, 1998